Recent research indicates that the psychedelic drug MDMA, commonly known as Ecstasy or Molly, has the potential to alleviate symptoms of post-traumatic stress disorder (PTSD), and it is expected that this treatment will be approved by the FDA in 2024.
The Multidisciplinary Association for Psychedelic Studies (MAPS), a non-profit organization founded in 1986, sponsored the study. MAPS focuses on the medical, legal, and cultural aspects of the responsible use of psychedelics and marijuana to benefit individuals.
“Thanks to the collaboration of therapists, volunteers participating in MAPS-sponsored trials, and generous donors, MDMA-assisted therapy for PTSD is on track to gain FDA approval in 2024,” said Rick Doblin, the founder and president of MAPS.
AUSTRALIA BECOMES 1ST COUNTRY TO ALLOW PATIENTS WITH DEPRESSION, PTSD TAKE PSYCHEDELICS
Image: Human brain stimulation or activity with neuron close-up 3D rendering illustration. Neurology, cognition, neuronal network, psychology, neuroscience scientific concepts.
(iStock)
The findings of the third phase of the study were published in Nature Medicine on September 13, 2024.
As part of the study, 104 individuals diagnosed with PTSD were randomly assigned to receive either MDMA or a placebo pill over three sessions spread one month apart. Both groups also received talk therapy during the sessions.
One participant dropped out of the MDMA group during the study, and the side effects experienced by the MDMA group included nausea, sweating, muscle tightness, and decreased appetite.
MIGRAINE NASAL SPRAY FROM PFIZER SNAGS FDA APPROVAL FOR EXPECTED SUMMER LAUNCH
Denial of responsibility! Vigour Times is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
Denial of responsibility! Vigour Times is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
